Singapore, June 30 -- Innovent Biologics, Inc. has announced that China's National Medical Products Administration (NMPA) has approved mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, for chronic weight management in Chinese adults with overweight or obesity.

Mazdutide is the world's first dual GCG/GLP-1 receptor agonist approved for weight loss, offering a unique mechanism that enhances weight-loss efficacy while reducing visceral fat and delivering comprehensive metabolic benefits.

The increasing prevalence of overweight and obesity in China poses an urgent public health challenge requiring immediate intervention.In April 2025, the National Health Commission officially included "Healthy...